stock-detail (DMPI)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/21/2017 06:17 am

4/21/2017 06:17 am

4/21/2017 06:17 am

4/21/2017 06:17 am

4/21/2017 06:17 am

4/13/2017 06:17 am

4/13/2017 06:17 am

4/13/2017 06:17 am

4/13/2017 06:17 am

4/13/2017 06:17 am

4/12/2017 12:17 pm

4/12/2017 12:17 pm

4/12/2017 12:17 pm

4/12/2017 12:17 pm

4/12/2017 12:17 pm

DelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017

3/28/2017 12:03 pm

[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., March 28, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it will present three abstracts at the American Association of Cancer Research (AACR) Annual Meeting. The abstracts are based on research conducted with DelMar's lead anti-cancer product candidate, VAL-083 (dianhydrogalactitol), a "first-in-class" small-molecule DNA-targeting agent. The AACR Annual Meeting will be held April 1-5, 2017 in Washington, D.C.

DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD

3/2/2017 01:03 pm

[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., March 2, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, will participate in a Key Opinion Leader forum highlighting the Company's novel treatment for patients suffering from glioblastoma multiforme ("GBM"). The luncheon forum takes place on Thursday, March 9th at 12:00pm EST at the Lotte New York Palace Hotel in New York City.

DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

2/13/2017 01:04 pm

[PR Newswire] - The first patient was dosed by DelMar's collaborators at the University of Texas MD Anderson Cancer Center in Houston Texas. "The dosing of the first subject in this VAL-083 trial marks an important milestone in the advancement of our clinical development program targeting MGMT-unmethylated GBM," said Jeffrey Bacha, chairman & CEO of DelMar Pharmaceuticals.